Minneapolis Portfolio Management Group LLC Has $26.02 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Minneapolis Portfolio Management Group LLC grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 131.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 264,114 shares of the medical equipment provider’s stock after buying an additional 149,888 shares during the quarter. Zimmer Biomet makes up 3.0% of Minneapolis Portfolio Management Group LLC’s portfolio, making the stock its 21st largest position. Minneapolis Portfolio Management Group LLC owned about 0.13% of Zimmer Biomet worth $26,015,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Legacy Wealth Asset Management LLC increased its position in shares of Zimmer Biomet by 2.3% in the third quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock valued at $460,000 after acquiring an additional 106 shares during the last quarter. Global Retirement Partners LLC increased its position in shares of Zimmer Biomet by 7.0% during the 3rd quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock worth $166,000 after purchasing an additional 111 shares during the last quarter. Generali Asset Management SPA SGR raised its stake in shares of Zimmer Biomet by 0.9% during the 3rd quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock worth $1,402,000 after purchasing an additional 122 shares in the last quarter. Brookstone Capital Management raised its stake in shares of Zimmer Biomet by 1.3% during the 3rd quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock worth $921,000 after purchasing an additional 123 shares in the last quarter. Finally, TD Private Client Wealth LLC boosted its holdings in shares of Zimmer Biomet by 14.0% in the 3rd quarter. TD Private Client Wealth LLC now owns 999 shares of the medical equipment provider’s stock valued at $98,000 after buying an additional 123 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $87.42 on Friday. The stock has a market cap of $17.32 billion, a PE ratio of 21.64, a P/E/G ratio of 2.26 and a beta of 0.62. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.39 and a current ratio of 2.43. The firm has a 50-day moving average of $91.59 and a 200-day moving average of $96.46. Zimmer Biomet Holdings, Inc. has a 52-week low of $85.33 and a 52-week high of $114.44.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. The business had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. Zimmer Biomet’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.76%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on ZBH shares. Baird R W downgraded shares of Zimmer Biomet from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 16th. Royal Bank Of Canada decreased their price objective on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, November 6th. The Goldman Sachs Group cut shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 target price on the stock. in a report on Friday, January 9th. Johnson Rice set a $112.00 target price on shares of Zimmer Biomet in a research note on Wednesday, November 5th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $100.00 price target (down previously from $115.00) on shares of Zimmer Biomet in a research report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $107.33.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.